17-苯基-18,19,20-三去甲前列腺素E2 | 38315-43-4

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 17-苯基-18,19,20-三去甲前列腺素E2
• 英文名称: 17-phenyl-ω-trinor prostaglandin E₂
• 英文别名: 17-phenyl trinor prostaglandin E2；17-phenyl-ω-trinor PGE₂；17-phenyltrinor-PGE₂；CL 116147；17-phenyl-omega-trinor-PGE2；(Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
• CAS: 38315-43-4
• 化学式: C₂₃H₃₀O₅
• 分子量: 386.488
• InChiKey: FOBVMYJQWZOGGJ-XYRJXBATSA-N

物化性质

• 沸点：
  597.1±50.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)
• 溶解度：
  DMF：>100 mg/ml（来自氟前列醇）； DMSO：>100 mg/ml（来自氟前列醇）；乙醇：>100 mg/ml（来自氟前列醇）； PBS pH 7.2：>0.8 mg/ml（来自 17-苯基三

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  28
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• AMINO ACID SALTS OF PROSTAGLANDINS
  申请人：DeLong Mitchell A.

  公开号：US20100105775A1

  公开（公告）日：2010-04-29

  The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.

  本发明涉及新型氨基酸前列腺素盐及其制备和使用方法。
• Synergistic combination of an anti-IgE antibody and an EP2 receptor agonist
  申请人：Universitat Autònoma de Barcelona

  公开号：EP2818484A1

  公开（公告）日：2014-12-31

  The present invention relates to synergistic combinations, including immunoconjugates, of an anti-IgE antibody, such as omalizumab, with an EP2 receptor agonist and their use in the prevention or treatment of an IgE-mediated disorder, preferably asthma.

  本发明涉及抗 IgE 抗体（例如奥马珠单抗）与 EP2 受体激动剂的协同组合（包括免疫结合剂），以及它们在预防或治疗 IgE 介导的疾病（最好是哮喘）中的用途。
• Diagnosis and Prediction of Alzheimer's Disease
  申请人：Boutaud Olivier

  公开号：US20100021938A1

  公开（公告）日：2010-01-28

  Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β peptide (Aβ) in the brain. Aβ is derived from amyloid precursor protein (APP) by β- and γ-secretases, with the β form (sAPPβ) being associated with the disease state, and the α form (sAPPα) being associated with the non-disease state. The present inventor proposes that defined the ratio of sAPPα to sAPPβ or the ratio of CTFα to CTFβ provide and accurate diagnosis of the disease, as well as a predictor for asymptomatic patients at risk of developing AD. In addition, drug screening and monitoring of treatment effectiveness can exploit this same sAPPα/sAPPβ or CTFα/CTFβ ratio.
• US8470882B2
  申请人：——

  公开号：US8470882B2

  公开（公告）日：2013-06-25
• US8623918B2
  申请人：——

  公开号：US8623918B2

  公开（公告）日：2014-01-07